$0.3485
0.025.16%
At close: -
$0.3660
0.025.02%
After Hours: 5:33 PM EDT
Comments
Loading...
Mersana Therapeutics Analyst Ratings and Price Targets | NASDAQ:MRSN | Benzinga
Mersana Therapeutics Inc has a consensus price target of $6.38 based on the ratings of 9 analysts. The high is $14 issued by SVB Leerink on August 9, 2022. The low is $1 issued by Citigroup on July 28, 2023. The 3 most-recent analyst ratings were released by Citigroup, Baird, and JP Morgan on August 27, 2024, August 14, 2024, and March 19, 2024, respectively. With an average price target of $4.33 between Citigroup, Baird, and JP Morgan, there's an implied 1083.97% upside for Mersana Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Baird
JP Morgan
Wedbush
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Mersana Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/06/2025 | Buy Now | — | William Blair | Andy Hsieh19% | — | Initiates | → Outperform | Get Alert |
| 08/27/2024 | Buy Now | 1266.12% | Citigroup | Ashiq Mubarack36% | $6 → $5 | Maintains | Buy | Get Alert |
| 08/14/2024 | Buy Now | 719.67% | Baird | Colleen Kusy33% | $4 → $3 | Maintains | Neutral | Get Alert |
| 03/19/2024 | Buy Now | 1266.12% | JP Morgan | Brian Cheng37% | → $5 | Upgrade | Underweight → Neutral | Get Alert |
| 02/29/2024 | Buy Now | 1812.57% | Wedbush | David Nierengarten60% | $2 → $7 | Upgrade | Neutral → Outperform | Get Alert |
| 02/29/2024 | Buy Now | 2359.02% | Truist Securities | Asthika Goonewardene40% | $9 → $9 | Upgrade | Hold → Buy | Get Alert |
| 02/29/2024 | Buy Now | 1266.12% | Baird | Colleen Kusy33% | $1 → $5 | Maintains | Neutral | Get Alert |
| 02/29/2024 | Buy Now | 1812.57% | Guggenheim | Michael Schmidt49% | → $7 | Upgrade | Neutral → Buy | Get Alert |
| 12/04/2023 | Buy Now | 1266.12% | Citigroup | Ashiq Mubarack36% | $1 → $5 | Upgrade | Neutral → Buy | Get Alert |
| 07/28/2023 | Buy Now | 173.22% | Citigroup | Ashik Kurian36% | $10 → $1 | Downgrade | Buy → Neutral | Get Alert |
| 07/28/2023 | Buy Now | 173.22% | Baird | Colleen Kusy33% | $7 → $1 | Downgrade | Outperform → Neutral | Get Alert |
| 07/27/2023 | Buy Now | 446.45% | Wedbush | David Nierengarten60% | $12 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 07/27/2023 | Buy Now | — | Truist Securities | Asthika Goonewardene40% | — | Downgrade | Buy → Hold | Get Alert |
| 06/16/2023 | Buy Now | 2632.24% | Citigroup | Ashik Kurian36% | $15 → $10 | Maintains | Buy | Get Alert |
| 06/16/2023 | Buy Now | 1266.12% | JP Morgan | Brian Cheng37% | $11 → $5 | Downgrade | Overweight → Neutral | Get Alert |
| 06/15/2023 | Buy Now | 3725.14% | Guggenheim | Michael Schmidt49% | → $14 | Initiates | → Buy | Get Alert |
| 05/11/2023 | Buy Now | 3998.36% | Citigroup | Ashik Kurian36% | $12 → $15 | Maintains | Buy | Get Alert |
| 03/16/2023 | Buy Now | 2632.24% | JP Morgan | Brian Cheng37% | → $10 | Upgrade | Neutral → Overweight | Get Alert |
| 11/21/2022 | Buy Now | 3178.69% | Truist Securities | Asthika Goonewardene40% | → $12 | Initiates | → Buy | Get Alert |
| 08/09/2022 | Buy Now | 5364.48% | Baird | Colleen Kusy33% | $18 → $20 | Maintains | Outperform | Get Alert |
| 08/09/2022 | Buy Now | 3725.14% | SVB Leerink | Jonathan Chang39% | $13 → $14 | Maintains | Outperform | Get Alert |
| 05/09/2022 | Buy Now | 3725.14% | SVB Leerink | Jonathan Chang39% | $13 → $14 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Mersana Therapeutics (MRSN) stock?
The latest price target for Mersana Therapeutics (NASDAQ:MRSN) was reported by William Blair on February 6, 2025. The analyst firm set a price target for $0.00 expecting MRSN to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Mersana Therapeutics (MRSN)?
The latest analyst rating for Mersana Therapeutics (NASDAQ:MRSN) was provided by William Blair, and Mersana Therapeutics initiated their outperform rating.
When was the last upgrade for Mersana Therapeutics (MRSN)?
The last upgrade for Mersana Therapeutics Inc happened on March 19, 2024 when JP Morgan raised their price target to $5. JP Morgan previously had an underweight for Mersana Therapeutics Inc.
When was the last downgrade for Mersana Therapeutics (MRSN)?
The last downgrade for Mersana Therapeutics Inc happened on July 28, 2023 when Citigroup changed their price target from $10 to $1 for Mersana Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Mersana Therapeutics (MRSN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mersana Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mersana Therapeutics was filed on February 6, 2025 so you should expect the next rating to be made available sometime around February 6, 2026.
Is the Analyst Rating Mersana Therapeutics (MRSN) correct?
While ratings are subjective and will change, the latest Mersana Therapeutics (MRSN) rating was a initiated with a price target of $0.00 to $0.00. The current price Mersana Therapeutics (MRSN) is trading at is $0.37, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.